155 related articles for article (PubMed ID: 12165509)
1. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4.
Tivol EA; Gorski J
J Immunol; 2002 Aug; 169(4):1852-8. PubMed ID: 12165509
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
Khattri R; Auger JA; Griffin MD; Sharpe AH; Bluestone JA
J Immunol; 1999 May; 162(10):5784-91. PubMed ID: 10229811
[TBL] [Abstract][Full Text] [Related]
3. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Tivol EA; Borriello F; Schweitzer AN; Lynch WP; Bluestone JA; Sharpe AH
Immunity; 1995 Nov; 3(5):541-7. PubMed ID: 7584144
[TBL] [Abstract][Full Text] [Related]
4. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.
Tivol EA; Boyd SD; McKeon S; Borriello F; Nickerson P; Strom TB; Sharpe AH
J Immunol; 1997 Jun; 158(11):5091-4. PubMed ID: 9164923
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition.
Chambers CA; Allison JP
Cold Spring Harb Symp Quant Biol; 1999; 64():303-12. PubMed ID: 11232300
[No Abstract] [Full Text] [Related]
6. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
Waterhouse P; Penninger JM; Timms E; Wakeham A; Shahinian A; Lee KP; Thompson CB; Griesser H; Mak TW
Science; 1995 Nov; 270(5238):985-8. PubMed ID: 7481803
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
Bachmann MF; Köhler G; Ecabert B; Mak TW; Kopf M
J Immunol; 1999 Aug; 163(3):1128-31. PubMed ID: 10415006
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen.
Walker LS; Ausubel LJ; Chodos A; Bekarian N; Abbas AK
J Immunol; 2002 Dec; 169(11):6202-9. PubMed ID: 12444125
[TBL] [Abstract][Full Text] [Related]
9. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor.
Chambers CA; Kang J; Wu Y; Held W; Raulet DH; Allison JP
Blood; 2002 Jun; 99(12):4509-16. PubMed ID: 12036882
[TBL] [Abstract][Full Text] [Related]
10. B7-independent inhibition of T cells by CTLA-4.
Chikuma S; Abbas AK; Bluestone JA
J Immunol; 2005 Jul; 175(1):177-81. PubMed ID: 15972645
[TBL] [Abstract][Full Text] [Related]
11. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.
Gajewski TF; Fallarino F; Fields PE; Rivas F; Alegre ML
J Immunol; 2001 Mar; 166(6):3900-7. PubMed ID: 11238634
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4, a negative regulator of T-lymphocyte activation.
Waterhouse P; Marengère LE; Mittrücker HW; Mak TW
Immunol Rev; 1996 Oct; 153():183-207. PubMed ID: 9010724
[No Abstract] [Full Text] [Related]
13. CTLA-4 and tolerance: the biochemical point of view.
Chikuma S; Bluestone JA
Immunol Res; 2003; 28(3):241-53. PubMed ID: 14713717
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 regulates induction of anergy in vivo.
Greenwald RJ; Boussiotis VA; Lorsbach RB; Abbas AK; Sharpe AH
Immunity; 2001 Feb; 14(2):145-55. PubMed ID: 11239447
[TBL] [Abstract][Full Text] [Related]
15. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?
Allison JP; Chambers C; Hurwitz A; Sullivan T; Boitel B; Fournier S; Brunner M; Krummel M
Novartis Found Symp; 1998; 215():92-8; discussion 98-102, 186-90. PubMed ID: 9760573
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 engagement acts as a brake on CD4+ T cell proliferation and cytokine production but is not required for tuning T cell reactivity in adaptive tolerance.
Inobe M; Schwartz RH
J Immunol; 2004 Dec; 173(12):7239-48. PubMed ID: 15585846
[TBL] [Abstract][Full Text] [Related]
17. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
18. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
Hwang KW; Sweatt WB; Brown IE; Blank C; Gajewski TF; Bluestone JA; Alegre ML
J Immunol; 2002 Jul; 169(2):633-7. PubMed ID: 12097362
[TBL] [Abstract][Full Text] [Related]
20. Is CTLA-4 a master switch for peripheral T cell tolerance?
Bluestone JA
J Immunol; 1997 Mar; 158(5):1989-93. PubMed ID: 9036940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
